ARTICLE | Strategy
Preferring PCSK9s
How payers, PBMs are using ICER's analyses in PCSK9 coverage decisions
October 19, 2015 7:00 AM UTC
While the Institute for Clinical and Economic Review refines its value assessment of PCSK9 inhibitors, Express Scripts Holding Co. has already made its coverage decision for the new lipid lowering agents, and Prime Therapeutics LLC and Harvard Pilgrim Inc. have told BioCentury they plan to make coverage decisions for the mAbs in the next month.
On Oct. 6, Express Scripts announced it granted co-exclusive formulary status to Praluent alirocumab from Sanofi and Regeneron Pharmaceuticals Inc. and Repatha evolocumab from Amgen Inc. ...